These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38299259)

  • 1. Sacubitril/valsartan improves the prognosis of acute myocardial infarction: a meta-analysis.
    Wang F; Li C; Zhang X
    Coron Artery Dis; 2024 May; 35(3):231-238. PubMed ID: 38299259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis.
    Zhang L; Yan K; Zhao H; Shou Y; Chen T; Chen J
    Ann Palliat Med; 2022 Mar; 11(3):1017-1027. PubMed ID: 35365031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article.
    Lin J; Zhou J; Xie G; Liu J
    Medicine (Baltimore); 2021 Dec; 100(52):e28231. PubMed ID: 34967357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials.
    Rindone JP; Mellen CK
    Eur J Clin Pharmacol; 2024 Aug; 80(8):1113-1120. PubMed ID: 38597935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.
    Xiong B; Nie D; Qian J; Yao Y; Yang G; Rong S; Zhu Q; Du Y; Jiang Y; Huang J
    ESC Heart Fail; 2021 Dec; 8(6):4852-4862. PubMed ID: 34716749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial.
    Yin H; Ma L; Zhou Y; Tang X; Li R; Zhou Y; Shi J; Zhang J
    Heart Vessels; 2024 Aug; 39(8):673-686. PubMed ID: 38635062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
    Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
    BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis.
    Zhao J; Zeng Y; Shen X
    Clin Cardiol; 2021 Oct; 44(10):1354-1359. PubMed ID: 34464468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects and Safety of Sacubitril/Valsartan for Patients with Myocardial Infarction: A Systematic Review and Meta-Analysis.
    Liu L; Ding X; Han Y; Lv J
    J Healthc Eng; 2022; 2022():7840852. PubMed ID: 35035857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    Pfeffer MA; Claggett B; Lewis EF; Granger CB; Køber L; Maggioni AP; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; Berwanger O; Cikes M; De Pasquale CG; East C; Fernandez A; Jering K; Landmesser U; Mehran R; Merkely B; Vaghaiwalla Mody F; Petrie MC; Petrov I; Schou M; Senni M; Sim D; van der Meer P; Lefkowitz M; Zhou Y; Gong J; Braunwald E;
    N Engl J Med; 2021 Nov; 385(20):1845-1855. PubMed ID: 34758252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.
    Zhou W; Yang X; Jin J; Cheng M; Li Y; Bai Y; Xu J
    Int Urol Nephrol; 2024 Jan; 56(1):181-190. PubMed ID: 37195574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
    Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
    Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
    Mehran R; Steg PG; Pfeffer MA; Jering K; Claggett B; Lewis EF; Granger C; Køber L; Maggioni A; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Ducrocq G; Berwanger O; De Pasquale CG; Landmesser U; Petrie M; Leng DSK; van der Meer P; Lefkowitz M; Zhou Y; Braunwald E
    Circulation; 2022 Dec; 146(23):1749-1757. PubMed ID: 36321459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    Mou Y; Qin L; Wang L; Guo Y; Zhang X; Yu J
    Altern Ther Health Med; 2024 Apr; 30(4):190-197. PubMed ID: 37917889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
    Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.